163 related articles for article (PubMed ID: 31302306)
21. Occurrence of Colorectal Cancer and the Influence of Medical Treatment in Patients With Inflammatory Bowel Disease: A Danish Nationwide Cohort Study, 1997 to 2015.
Weimers P; Ankersen DV; Løkkegaard ECL; Burisch J; Munkholm P
Inflamm Bowel Dis; 2021 Oct; 27(11):1795-1803. PubMed ID: 33409534
[TBL] [Abstract][Full Text] [Related]
22. Risk Factors for the Occurrence and Severity of Vertebral Fractures in Inflammatory Bowel Disease Patients: A Nationwide Population-Based Cohort Study.
Choi A; Jung SH; Kim S; Lee JS
J Korean Med Sci; 2023 Jul; 38(28):e210. PubMed ID: 37463684
[TBL] [Abstract][Full Text] [Related]
23. Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
Horton N; Wu X; Philpott J; Garber A; Achkar JP; Brzezinski A; Lashner BA; Shen B
Dig Dis Sci; 2016 Nov; 61(11):3270-3277. PubMed ID: 27619393
[TBL] [Abstract][Full Text] [Related]
24. Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
Mahmoud R; Savelkoul EHJ; Mares W; Goetgebuer R; Witteman BJM; de Koning DB; van Tuyl SAC; Minderhoud I; Lutgens MWMD; Akol-Simsek D; van Schaik FDM; Fidder HH; Jansen JM; van Boeckel PGA; Mahmmod N; Horjus-Talabur Horje CS; Römkens TEH; Colombel JF; Hoentjen F; Jharap B; Oldenburg B;
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):750-760.e4. PubMed ID: 36055567
[TBL] [Abstract][Full Text] [Related]
25. Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study.
Biancone L; Armuzzi A; Scribano ML; Castiglione F; D'Incà R; Orlando A; Papi C; Daperno M; Vecchi M; Riegler G; Fries W; Alvisi P; Meucci G; Mocciaro F; Rogai F; Festa S; Guidi L; Testa A; Spina L; Renna S; Viola A; Patturelli M; Di Mitri R; Frankovic I; Calabrese E; Petruzziello C; De Cristofaro E; Sena G; Ruffa A; Neri B; Rossi A
Inflamm Bowel Dis; 2020 Feb; 26(3):450-459. PubMed ID: 31498388
[TBL] [Abstract][Full Text] [Related]
26. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
27. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
28. Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
Boyapati RK; Torres J; Palmela C; Parker CE; Silverberg OM; Upadhyaya SD; Nguyen TM; Colombel JF
Cochrane Database Syst Rev; 2018 May; 5(5):CD012540. PubMed ID: 29756637
[TBL] [Abstract][Full Text] [Related]
29. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis.
Ananthakrishnan AN; Long MD; Martin CF; Sandler RS; Kappelman MD
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):965-71. PubMed ID: 23376797
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.
Breton J; Kastl A; Hoffmann N; Rogers R; Grossman AB; Mamula P; Kelsen JR; Baldassano RN; Albenberg L
Inflamm Bowel Dis; 2019 Aug; 25(9):1586-1593. PubMed ID: 30715364
[TBL] [Abstract][Full Text] [Related]
31. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study.
Biancone L; Zuzzi S; Ranieri M; Petruzziello C; Calabrese E; Onali S; Ascolani M; Zorzi F; Condino G; Iacobelli S; Pallone F
J Crohns Colitis; 2012 Jun; 6(5):578-87. PubMed ID: 22398047
[TBL] [Abstract][Full Text] [Related]
32. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
[TBL] [Abstract][Full Text] [Related]
33. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
34. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
35. Treatment Options and Outcomes of Pediatric IBDU Compared with Other IBD Subtypes: A Retrospective Multicenter Study from the IBD Porto Group of ESPGHAN.
Aloi M; Birimberg-Schwartz L; Buderus S; Hojsak I; Fell JM; Bronsky J; Veereman G; Koletzko S; Shaoul R; Miele E; Turner D; Russell RK
Inflamm Bowel Dis; 2016 Jun; 22(6):1378-83. PubMed ID: 27135479
[TBL] [Abstract][Full Text] [Related]
36. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L; Rahier JF; Kirchgesner J; Abitbol V; Shaji S; Armuzzi A; Karmiris K; Gisbert JP; Bossuyt P; Helwig U; Burisch J; Yanai H; Doherty GA; Magro F; Molnar T; Löwenberg M; Halfvarson J; Zagorowicz E; Rousseau H; Baumann C; Baert F; Beaugerie L;
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):771-788.e10. PubMed ID: 36152897
[TBL] [Abstract][Full Text] [Related]
37. Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies.
Rozich JJ; Dulai PS; Fumery M; Sandborn WJ; Singh S
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2437-2447.e6. PubMed ID: 32142940
[TBL] [Abstract][Full Text] [Related]
38. Comparison of inflammatory bowel disease relapse after top-down or step-up therapy: a population-based cohort study.
Ochi M; Niikura R; Otsubo T; Yamada A; Kawai T; Koike K
Int J Colorectal Dis; 2021 Oct; 36(10):2227-2235. PubMed ID: 34386841
[TBL] [Abstract][Full Text] [Related]
39. Increased risk of genital warts in inflammatory bowel disease: A Danish registry-based cohort study (1996-2018).
Elmahdi R; Thomsen LT; Iversen AT; Allin KH; Kjaer SK; Jess T
United European Gastroenterol J; 2022 Apr; 10(3):287-295. PubMed ID: 35297191
[TBL] [Abstract][Full Text] [Related]
40. Factors Associated with Inflammatory Bowel Disease Flare During Pregnancy Among Women with Preconception Remission.
Rottenstreich A; Shifman Z; Grisaru-Granovksy S; Mishael T; Koslowsky B; Bar-Gil Shitrit A
Dig Dis Sci; 2021 Apr; 66(4):1189-1194. PubMed ID: 32356256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
